BiotechTube

Solifenacin succinate

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurogenic Detrusor Overactivity

Conditions

Neurogenic Detrusor Overactivity, Pediatric

Trial Timeline

Sep 25, 2013 → Dec 18, 2015

NCT ID
NCT01981954

About Solifenacin succinate

Solifenacin succinate is a phase 3 stage product being developed by Astellas Pharma for Neurogenic Detrusor Overactivity. The current trial status is completed. This product is registered under clinical trial identifier NCT01981954. Target conditions include Neurogenic Detrusor Overactivity, Pediatric.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (7)

NCT IDPhaseStatus
NCT00189800Phase 3Completed
NCT01981954Phase 3Completed
NCT01565694Phase 3Completed
NCT00909428ApprovedCompleted
NCT00337558ApprovedCompleted
NCT00463541Phase 3Completed
NCT00454740Phase 3Completed

Competing Products

20 competing products in Neurogenic Detrusor Overactivity

See all competitors
ProductCompanyStageHype Score
MirabegronAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
MirabegronAstellas PharmaPhase 1
33
mirabegronAstellas PharmaPhase 3
77
SAF312 + Placebo to SAF312NovartisPhase 2
52
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from FreiburgPfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)PfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
alfuzosin (SL770499)SanofiPhase 3
76
Alfuzosin + PlaceboSanofiPhase 3
76
Droxidopa capsules + Placebo capsulesLundbeckApproved
82
Rec 0/0438 1 mg or Rec 0/0438 2 mg + placeboRecordatiPhase 1/2
38
Ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
TD-9855 + PlaceboTheravance BiopharmaPhase 2
47
ampreloxetineTheravance BiopharmaPhase 3
72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin PlaceboTheravance BiopharmaPhase 1
28
AmpreloxetineTheravance BiopharmaPhase 1
28

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85